Cancer immunotherapy--the endgame begins - PubMed (original) (raw)

Comment

Cancer immunotherapy--the endgame begins

Louis M Weiner. N Engl J Med. 2008.

No abstract available

PubMed Disclaimer

Figures

Figure 1

Tumors evade or defeat the host tumor response to obtain a host-specific selective survival advantage.

Comment in

• Cancer immunotherapy.
  Prestwich R, Vile R, Melcher A. Prestwich R, et al. N Engl J Med. 2008 Sep 4;359(10):1072; author reply 1073. N Engl J Med. 2008. PMID: 18777615 No abstract available.

Comment on

• Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.
  Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C. Hunder NN, et al. N Engl J Med. 2008 Jun 19;358(25):2698-703. doi: 10.1056/NEJMoa0800251. N Engl J Med. 2008. PMID: 18565862 Free PMC article.
• Cancer immunology.
  Finn OJ. Finn OJ. N Engl J Med. 2008 Jun 19;358(25):2704-15. doi: 10.1056/NEJMra072739. N Engl J Med. 2008. PMID: 18565863 Review. No abstract available.

Similar articles

• STING signaling: a key to therapeutic tumor immunity.
  Foote JB, Emens LA. Foote JB, et al. Immunotherapy. 2018 Jul;10(9):729-731. doi: 10.2217/imt-2018-0064. Immunotherapy. 2018. PMID: 30008260 No abstract available.
• Human Tumor Antigens and Cancer Immunotherapy.
  Vigneron N. Vigneron N. Biomed Res Int. 2015;2015:948501. doi: 10.1155/2015/948501. Epub 2015 Jun 16. Biomed Res Int. 2015. PMID: 26161423 Free PMC article. Review.
• Introduction: Cancer Immunology Special Issue-Immunotherapy.
  Kawakami Y. Kawakami Y. Int Immunol. 2016 Jul;28(7):317. doi: 10.1093/intimm/dxw028. Epub 2016 Jun 15. Int Immunol. 2016. PMID: 27313100 No abstract available.
• Recruiting T cells in cancer immunotherapy.
  Yost KE, Chang HY, Satpathy AT. Yost KE, et al. Science. 2021 Apr 9;372(6538):130-131. doi: 10.1126/science.abd1329. Science. 2021. PMID: 33833111 No abstract available.
• Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant.
  Overwijk WW. Overwijk WW. Curr Opin Immunol. 2017 Aug;47:103-109. doi: 10.1016/j.coi.2017.07.015. Epub 2017 Aug 12. Curr Opin Immunol. 2017. PMID: 28806603 Review.

Cited by

• Combined inflammatory parameters and tertiary lymphoid structure predict prognosis in patients with resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
  Xu F, Zhu H, Dong Y, Li L, Liu N, Yuan S. Xu F, et al. Front Immunol. 2023 Dec 14;14:1244256. doi: 10.3389/fimmu.2023.1244256. eCollection 2023. Front Immunol. 2023. PMID: 38155965 Free PMC article.
• Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.
  Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, Levy R. Marabelle A, et al. J Clin Invest. 2013 Jun;123(6):2447-63. doi: 10.1172/JCI64859. J Clin Invest. 2013. PMID: 23728179 Free PMC article.
• Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses.
  Oh DS, Kim H, Oh JE, Jung HE, Lee YS, Park JH, Lee HK. Oh DS, et al. Oncotarget. 2017 Jul 18;8(29):47440-47453. doi: 10.18632/oncotarget.17663. Oncotarget. 2017. PMID: 28537894 Free PMC article.
• Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy.
  Gerber SA, Sorensen EW, Sedlacek AL, Lim JY, Skrombolas D, Frelinger JG, Lord EM. Gerber SA, et al. Immunology. 2013 Mar;138(3):280-92. doi: 10.1111/imm.12037. Immunology. 2013. PMID: 23198850 Free PMC article.
• Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.
  AlDeghaither D, Smaglo BG, Weiner LM. AlDeghaither D, et al. J Clin Pharmacol. 2015 Mar;55 Suppl 3(0 3):S4-20. doi: 10.1002/jcph.407. J Clin Pharmacol. 2015. PMID: 25707963 Free PMC article. Review.

References

1. 1. Durant JR. Immunotherapy of cancer: the end of the beginning? N Engl J Med. 1987 Apr 9;316(15):939–941. PMID: 3493434. - PubMed
2. 1. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. PMID: 3493432. Blood. 1993 Oct 15;82(8):2310-8. - PubMed
3. 1. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van Tuinen P, Horowitz MM, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood. 1993 Oct 15;82(8):2310–2318. - PubMed
4. 1. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001 Apr 26;410(6832):1107–1111. PMID:11323675. - PubMed
5. 1. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006 Oct 6;314(5796):126–129. Epub 2006 Aug 31. PMID: 16946036. - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

• R01 CA050633/CA/NCI NIH HHS/United States
• R01 CA050633-18/CA/NCI NIH HHS/United States
• R01 CA121033/CA/NCI NIH HHS/United States
• R01 CA121033-02/CA/NCI NIH HHS/United States

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central